Study guide

14.3 Anemias & Oncology Supportive Care

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

14.3 Anemias & Oncology Supportive Care

Key Takeaways Explain This Topic AI

Iron deficiency in men and postmenopausal women needs investigation for GI blood loss; oral iron is taken once daily or on alternate days, separated from levothyroxine and other chelating drugs.

Continue oral iron for about 3 months after hemoglobin normalizes, and use IV iron for intolerance, malabsorption or advanced CKD.

High-dose oral vitamin B12 (1,000 to 2,000 mcg daily) is effective even in pernicious anemia, and B12 deficiency must be excluded before treating with folate alone.

Highly emetogenic chemotherapy such as cisplatin needs an NK1 antagonist, a 5-HT3 antagonist, dexamethasone and olanzapine.

Fever of 38.3°C or more after chemotherapy may be febrile neutropenia and needs immediate assessment and IV antibiotics.

Last updated: October 2026

Anemias & Oncology Supportive Care

Anemia is a common finding in community practice. The pharmacist's role is to support the right replacement therapy and to recognize when an underlying cause needs investigating. Most patients with cancer now receive at least part of their treatment at home. Community pharmacists therefore manage antiemetics, oral anticancer drugs, infection warnings and safe handling.

1. Iron-Deficiency Anemia

Diagnosis: microcytic anemia with ferritin below 30 µg/L . Ferritin can be falsely normal in inflammation, where values up to about 100 µg/L may still mean iron deficiency.

Look for the cause: in men and postmenopausal women, iron deficiency is GI blood loss until proven otherwise and needs referral for investigation . Other causes are heavy menstrual bleeding, pregnancy, malabsorption (celiac disease, bariatric surgery), and NSAID or anticoagulant-related bleeding.

Oral iron:

Elemental iron content: ferrous sulfate 300 mg ≈ 60 mg; ferrous gluconate 300 mg ≈ 35 mg; ferrous fumarate 300 mg ≈ 100 mg.

Dose once daily, or on alternate days. Each dose raises hepcidin for about 24 hours, so splitting doses through the day adds GI effects but little absorption.

Take on an empty stomach , with water or a vitamin C source. Take with food if GI upset limits adherence.

Separate iron from levothyroxine (about 4 hours), fluoroquinolones, tetracyclines, calcium, antacids and bisphosphonates. PPIs reduce absorption.

Expected response: reticulocytes rise within about 7 to 10 days and hemoglobin by about 10 to 20 g/L within 2 to 4 weeks . Continue for about 3 months after hemoglobin normalizes to rebuild stores.

Counsel that dark stools are expected. Black, tarry, sticky stools with weakness suggest bleeding and need assessment.

IV iron (iron sucrose, ferric derisomaltose, ferric carboxymaltose) is used for intolerance, malabsorption, ongoing losses, advanced CKD, or the need for rapid repletion before surgery.

2. Vitamin B12 and Folate Deficiency

Vitamin B12 deficiency causes macrocytic anemia and neurological symptoms : neuropathy, cognitive change and gait problems.

Causes: pernicious anemia, gastric surgery, a strict vegan diet, and long-term metformin or PPI use. Check B12 periodically in long-term metformin users.

Treatment: high-dose oral cyanocobalamin (1,000 to 2,000 mcg daily) works even in pernicious anemia, because passive absorption does not need intrinsic factor. IM injections are used for severe deficiency or neurological involvement.

Folate deficiency: folic acid 1 to 5 mg daily. Rule out B12 deficiency first. Folate alone can correct the anemia while neurological damage from B12 deficiency progresses.

Pregnancy planning: folic acid supplementation starts before conception (section 15.3).

3. Chemotherapy-Induced Nausea and Vomiting (CINV)

Prophylaxis depends on the emetogenic risk of the regimen:

Emetic risk Example agents Recommended prophylaxis (acute phase)

High (> 90%) Cisplatin; anthracycline plus cyclophosphamide NK1 antagonist (aprepitant or fosaprepitant) + 5-HT3 antagonist (ondansetron, granisetron, palonosetron) + dexamethasone + olanzapine

Moderate (30–90%) Oxaliplatin, irinotecan, carboplatin 5-HT3 antagonist + dexamethasone (add an NK1 antagonist for carboplatin at higher doses)

  • Low Taxanes, gemcitabine, 5-FU A single agent (dexamethasone or a 5-HT3 antagonist)
  • Minimal Many monoclonal antibodies No routine prophylaxis

Delayed nausea (days 2 to 4) is treated with dexamethasone and/or olanzapine. Ondansetron adds little in the delayed phase.

Breakthrough: olanzapine, or a dopamine antagonist such as metoclopramide or prochlorperazine (watch for extrapyramidal reactions). Doses are scheduled, not left until vomiting starts.

Anticipatory nausea: prevented by good control from the first cycle; lorazepam before treatment.

Practical pearls:

Ondansetron: constipation, headache and QT prolongation.

Dexamethasone: in the morning (insomnia), and monitor glucose.

Aprepitant: CYP3A4 interactions. It raises dexamethasone levels (reduce the dexamethasone dose), lowers warfarin effect, and reduces hormonal contraceptive efficacy for 28 days .

Missed doses: a patient on scheduled before-meal metoclopramide who misses the breakfast dose and will be home just before lunch should skip the missed dose and take the next scheduled one. Missed doses are taken when remembered only if the next dose is not due soon, and doses are never doubled. PEBC's sample items use exactly this case.

4. Febrile Neutropenia and Other Supportive Care

Warning

Febrile neutropenia is an emergency. Fever (a single temperature of 38.3°C or higher, or 38.0°C sustained over an hour ) with an absolute neutrophil count below 0.5 × 10⁹/L , or expected to fall below it, needs immediate assessment and empiric IV antibiotics within about an hour. Patients should not treat a fever with acetaminophen at home without calling their oncology team, because it can mask fever.

Granulocyte colony-stimulating factors (filgrastim, pegfilgrastim, and their biosimilars) are used as primary prophylaxis when a regimen's febrile neutropenia risk is 20% or higher , or 10 to 20% with patient risk factors. Bone pain is common and responds to acetaminophen or loratadine.

Oral anticancer drugs:

Hazardous handling: wash hands, wear gloves for caregivers, do not crush or split, and return unused drugs to the pharmacy.

Adherence and dosing: check for complex schedules (for example, capecitabine twice daily after meals for 14 days of a 21-day cycle).

Interactions: many kinase inhibitors are CYP3A4 substrates, and some need gastric acid to dissolve, so PPIs reduce absorption. Capecitabine raises warfarin effect.

Mucositis: bland rinses (salt and baking soda in water), soft toothbrush, no alcohol-based mouthwashes.

Tumour lysis syndrome prevention in high-risk cancers: hydration plus allopurinol, or rasburicase (contraindicated in G6PD deficiency).

Hypercalcemia of malignancy: IV hydration, then zoledronic acid or denosumab.

Cancer-associated thrombosis is covered in section 8.3.